HER-2 status in gastrointestinal stromal tumor

Annals of Diagnostic Pathology

Volumn 12, Issue 4, 2008, Pages 283-285

  Lopes, Lisandro Ferreira ^a   Bacchi, Carlos E ^a  

^a Consultoria em Patologia ^*  (Brazil)

Author keywords

Fluorescence in situ hybridization; Gastrointestinal stromal tumor; HER 2; HercepTest; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

GASTROINTESTINAL STROMAL TUMORS; GENE DOSAGE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 46949084274     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2008.02.007     Document Type: Article

References (16)

1. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Maguire Jr. H.C., and Greene M.I. The neu (c-erbB-2) oncogene. Semin Oncol 16 (1989) 148-155
3. Tandon, Clark G.M., Chamness G.C., et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7 (1989) 1120-1128
4. Gusterson, Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (1992) 1049-1056
5. Dougall W.C., Qian X., Peterson N.C., et al. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9 (1994) 2109-2123
6. Menard S., Casalini P., Campiglio M., Pupa S.M., and Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61 (2004) 2965-2978
7. Johnson P.H., and Esteva F.J. The use of HER2 modulation in the adjuvant setting. Curr Oncol Rep 9 (2007) 9-16
8. Meric-Bernstam, and Hung M.C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12 (2006) 6326-6330
9. Rubin B.P. Gastrointestinal stromal tumours: an update. Histopathology 48 (2006) 83-96
10. Miettinen M., and Lasota J. Gastrointestinal stromal tumours. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130 (2006) 1466-1478
11. Savage, and Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346 (2002) 683-693
12. Cai Y.C., Jiang Z., Vittimberga F., et al. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 435 (1999) 112-115
13. Tornillo L., Duchini G., Carafa V., et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 85 (2005) 921-931
14. Lanzafame S., Minutolo V., Caltabiano R., et al. About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor. Pathol Res Pract 202 (2006) 119-123
15. Yoo N.J., Lee J.W., Soung Y.H., et al. Mutational analysis of the epidermal growth factor receptor gene in gastrointestinal stromal tumors. J Korean Gastric Cancer Assoc 4 (2004) 268-271
16. Lopes L.F., and Bacchi C.E. EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases. Mod Pathol 20 (2007) 990-994